As a result, PARP inhibitors have been widely used in pre-clinical and clinical settings [75] and phase 2 results with Iniparib (Sanofi-Aventis) were impressive in triple negative breast cancers (TNBC), an aggressive form of breast cancer. This evidence concerns the gene PARP1 and breast carcinoma.